SEATTLE, July 23, 2014 (GLOBE NEWSWIRE) -- Attorney Advertising. Keller Rohrback L.L.P. is investigating claims that Xarelto (rivaroxaban), an anticoagulant drug used both to treat and prevent blood clots, causes serious and unrestrained internal bleeding which could result in severe, life-threatening injuries, or even death.
It has been alleged that Xarelto did not properly advise patients or physicians regarding certain risks, including irreversible or uncontrollable bleeding, and that internal bleeding cannot be reversed as easily as with other anticoagulants.
The Food and Drug Administration allowed Xarelto drugmakers to expand its use in 2012 by allowing the drug to be used as a treatment for deep vein thrombosis or pulmonary embolism, but rejected their 2014 attempt to market the pill for prevention of heart attacks and strokes in patients with acute coronary syndrome.
If you or someone you know became ill or suffered a serious side effect after using Xarelto, please contact attorneys Gretchen Freeman Cappio, Dan Mensher, Michael Woerner, or Mark Samson at 800.776.6044 or via email to learn more about your rights.
Keller Rohrback, with offices in Seattle, Phoenix, New York, and Santa Barbara, has successfully represented hundreds of clients injured by prescription drugs such as Fen-Phen, Baycol, and Vioxx. Our Complex Litigation Group is proud to offer its expertise in personal injury cases to clients nationwide. Keller Rohrback's trial lawyers have obtained judgments and settlements on behalf of clients in excess of seven billion dollars.
Attorney Advertising. Prior Results Do Not Guarantee A Similar Outcome.